BI Starts Clinical Study on Interchangeability | Boehringer Ingelheim US
BI announced today that the first patient has been enrolled into its VOLTAIRE-X interchangeability study, for an adalimumab biosimilar candidate.
Search
Disability Inclusion at Work: Top Score | Boehringer Ingelheim US
Click here to read more on Boehringer Ingelheim receiving a 100 score with Disability:IN’s “Best Place to Work for Disability Inclusion” for the 5th year!
Could decentralised trials transform the way we view depression?
Could decentralised trials transform the way we view depression? Dr Vikas Mohan Sharma believes this could deliver meaningful changes for patients all arround.
Our culture
Our culture reflects who we are and is reflected in Our FOCUS and strong belief in Diversity, Equity and Inclusion as well as Sustainable Development.
Ingelheim
The company headquarters of Boehringer Ingelheim are located in Ingelheim, Germany.
Sophia Malki: A Woman on the Rise
Sophia Malki: A Woman on the Rise
Our Innovation Strategy
Our innovation strategy focuses on developing a deep understanding of disease, identifying relevant disease mechanisms and using adequate therapeutic modalities to address them
Topline results from Boehringer's Phase III IPF Study
Press release announcing topline results of Boehringer Ingelheim's Phase III FIBRONEER-IPF study in indiopathic pulmonary fibrosis
Driving Innovation through Diversity & Inclusion
Driving innovation through diversity and inclusion. Inclusive leaders and an inclusive organisation allow diversity to flourish. Diversity is the mix. Inclusion is making the mix work.
Mental Health
Mental Health
Depression
Depression
Schizophrenia
Schizophrenia
Our forward-looking approach drives breakthroughs
Our purpose is the patient—so our actions are those of a partner, our vision is always long-term, and our results are measured in lives changed and lives saved.
Company History | Corporate Profile | Boehringer Ingelheim US
Click here to watch our video on the history of Boehringer Ingelheim, founded by Albert Boehringer in 1885.
Work life balance
It is important that employees have a balance between professional and personal lives, so we offer various leave options and flexible working schedules.
SEMINTRA® (Telmisartan Oral Solution) | Boehringer Ingelheim US
Introducing SEMINTRA® (telmisartan oral solution) —The first FDA-approved liquid solution for the control of systemic feline hypertension.
New Swine Vaccine Combination Released | Boehringer Ingelheim US
Click here to read more on the introduction of another new swine vaccination combination from Boehringer Ingelheim, protecting pigs from common viruses.
What can the Patient do?
What can the Patient do?
Vetmedica Inc to Sell Vaccine Portfolio | Boehringer Ingelheim US
Read more on Boehringer Ingelheim Vetmedica Inc. entering into an agreement to sell feline, canine and rabies vaccines to Elanco Animal Health in the USA.
Candice is moving to Germany
Are you considering a career at Boehringer Ingelheim? Find out why Candice loves working here. For more talent insights, visit our Careers Page.
About Us
Click here to discover more about Boehringer Ingelheim and our headquarters and largest U.S subsidiary in Connecticut.
Federal and State Laws
Federal and State Laws
Obesity
Obesity
Express Scripts Adds BI Products to Roster | BI US
Read more on Express Scripts adding the Spiriva Respimat, Spiriva Handihaler and Stiolto Respimat to their commercial national preferred formulary.
We’re investing $50 million in Puerto Rico. It will increase our ability to make products to protect pets.
We’re investing $50 million in Puerto Rico. It will increase our ability to make products to protect pets.